



BEAT BioTherapeutics Corporation

BEAT BioTherapeutic's co-founder, Dr. Michael Regnier, to present at American College of Cardiology Annual Meeting

(SEATTLE, WA) March 27, 2014 – BEAT BioTherapeutics Corporation (BEATBio) announced today that co-founder and Scientific Advisory Board member, Dr. Michael Regnier, will present at the upcoming American College of Cardiology Annual Scientific Sessions meeting on March 29, 2014 in Washington, D.C. Dr. Regnier is Professor and Vice Chairman of the Department of Bioengineering at the University of Washington. He also leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. Dr. Regnier is part of a multi-disciplinary team at BEATBio developing BB-R12, an exciting new therapy for heart failure. Dr. Regnier's presentation is titled *"Supercharging the Heart – Myofilament-Targeted Therapy for Heart Failure"*. His presentation is part the ACC's *"Emerging Pharmacotherapies in Heart Failure"* session that begins at 4:45 PM EDT.

About BEATBio: BEATBio is a Seattle, WA based biotechnology company focused on the development of a novel biological treatment for heart failure. BB-R12 therapy is based on the fundamental discovery that dATP is a superior fuel for cardiac muscle contraction than is ATP. BB-R12 is being developed to treat heart failure by increasing cardiac performance. BEATBio's founders, from the University of Washington, are recognized experts in cardiovascular biology, muscle physiology and bioengineering and have received nearly \$50MM of NIH funding. BEATBio holds worldwide rights to this technology and used a recently raised \$2.9MM seed financing to successfully complete the initial stages of pre-clinical development and manufacturing scale-up. BEATBio has assembled a strong team experts that allowed rapid achievement of significant development milestones in 2013. The company is now raising a Series A financing to complete IND-enabling studies and commence Phase I human trials.

Contact:

Michael Kranda, CEO
mkranda@BEATBiotherapeutics.com
(M) 425-647-4236

Gregory Mahairas, CSO
gmahairas@BEATBiotherapeutics.com
(M) 206 295-7905

Sam L. Teichman, CMO
steichman@BEATBiotherapeutics.com
(M) 925 437-2067